BridgeBio Pharma Ownership
| BBIO Stock | USD 72.01 0.29 0.40% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 190.5 M | Current Value 190.5 M | Avarage Shares Outstanding 142.7 M | Quarterly Volatility 33.3 M |
BridgeBio | Build AI portfolio with BridgeBio Stock |
BridgeBio Stock Ownership Analysis
About 100.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.05. BridgeBio Pharma recorded a loss per share of 4.21. The entity had not issued any dividends in recent years. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people. For more info on BridgeBio Pharma please contact the company at 650 391 9740 or go to https://bridgebio.com.Besides selling stocks to institutional investors, BridgeBio Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different BridgeBio Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align BridgeBio Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
BridgeBio Pharma Quarterly Liabilities And Stockholders Equity |
|
BridgeBio Pharma Insider Trades History
About 5.0% of BridgeBio Pharma are currently held by insiders. Unlike BridgeBio Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against BridgeBio Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of BridgeBio Pharma's insider trades
BridgeBio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BridgeBio Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BridgeBio Pharma backward and forwards among themselves. BridgeBio Pharma's institutional investor refers to the entity that pools money to purchase BridgeBio Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2025-06-30 | 2.8 M | Goldman Sachs Group Inc | 2025-06-30 | 2.6 M | Alliancebernstein L.p. | 2025-06-30 | 2.5 M | Laurion Capital Management Lp | 2025-06-30 | 2.4 M | Two Sigma Investments Llc | 2025-06-30 | 2.3 M | Macquarie Group Ltd | 2025-06-30 | 2.1 M | D. E. Shaw & Co Lp | 2025-06-30 | 2.1 M | Fmr Inc | 2025-06-30 | 2 M | Norges Bank | 2025-06-30 | 2 M | Viking Global Investors Lp | 2025-06-30 | 18.6 M | Vanguard Group Inc | 2025-06-30 | 16.5 M |
BridgeBio Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BridgeBio Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on BridgeBio Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BridgeBio Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BridgeBio Pharma's latest congressional trading
Congressional trading in companies like BridgeBio Pharma, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in BridgeBio Pharma by those in governmental positions are based on the same information available to the general public.
| 2025-10-13 | Representative Gilbert Cisneros | Acquired Under $15K | Verify |
BridgeBio Pharma Outstanding Bonds
BridgeBio Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BridgeBio Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BridgeBio bonds can be classified according to their maturity, which is the date when BridgeBio Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
BridgeBio Pharma Corporate Filings
F4 | 24th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of November 2025 Other Reports | ViewVerify | |
| 29th of October 2025 Other Reports | ViewVerify | |
| 14th of August 2025 Other Reports | ViewVerify |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with BridgeBio Stock
Moving against BridgeBio Stock
| 0.85 | OPTI | OptiBiotix Health Plc | PairCorr |
| 0.84 | OBI | Ondine Biomedical | PairCorr |
| 0.8 | ALVO | Alvotech | PairCorr |
| 0.72 | AVH | Avita Medical | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.21) | Revenue Per Share | Quarterly Revenue Growth 43.18 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.